Put Some Gay In Your Day, Dallas!

Let’s Do Shots! You Could Be One Of The First People To Test A New COVID-19 Vaccine.

The thought of a Covid-19 vaccine has given us all a little extra hope this holiday season, and now you have the opportunity to potentially participate in a clinical study taking place at Prism Health North Texas.

If eligible, you’ll receive compensation for your time and receive a stipend for each visit.

Read the full press release below for complete details:

“As 2020 comes to a close, hopes of a vaccine for the COVID-19 virus slowly continue to grow with promising results from a variety of pharmaceutical companies. One of the leaders of the industry, AstraZeneca Oxford, is expanding the late phase trials of its AZD1222 vaccine right here in the heart of North Texas. The acclaimed Research Department at Prism Health North Texas has been preparing to host trials of the AZD1222 vaccine for months and is now seeking participants for the trials.

Seeking 250 of the 30,000 required participants across the study, PHNTX invites North Texans with the following qualifications to contact their Research Department about participating in the study:

  • Those with underlying medical conditions
  • Those with greater risk of exposure at their jobs
  • Those living or working in elder-care facilities, jails, or prisons
  • Those over the age of 65 (participants must be 18 years or older)
  • Those in racial or ethnic groups that have been impacted in greater numbers such as African Americans, Latinx, and Native Americans

Those selected for the study will be compensated for their time and will receive a stipend for each visit they complete. Visits will be held at the Oak Cliff Health Center at 219 Sunset Avenue, Suite 116 and in a new satellite office in east Dallas at 4004 Worth Street.

Those interested in participating in the study may visit phntx.org/services/clinical-research and complete the contact form or email the Research Department directly at research@phntx.org. They will then be contacted by phone to discuss study participation and eligibility criteria.”